Want to Know MK-677’s Strength? Read This MK-677 Guide to Learn More
In this Ibutamoren guide, we will discuss several key benefits supported by existing MK-677 research.
People frequently mistake MK-677 (Ibutamoren/Nutrobal) for a steroid or SARM (selective androgen receptor modulator, which it is not.
MK-677 is a non-peptide ghrelin analogue, which functions as an orally active growth hormone secretagogue (releaser). Research shows that, in a dose-dependent manner, MK-677 will increase levels of growth hormone and IGF-1 in the blood. Compared to other growth hormone secretagogues which are mostly peptides such as GHRP-2, GHRP-6, Hexarelin and others, MK-677 has not been shown to increase cortisol levels. This is a very important and impressive property of this unique compound. Research has also shown that prolonged administration of MK-677 yielded greater and sustained elevations in growth hormone and IGF-1.
MK-677 was initially developed to mitigate IGF-1 and growth hormone deficiencies and complications that arise from this. However, elevations in growth hormone and IGF-1 levels also promote increased muscle growth and body fat loss. As a result, it is not surprising that people interested in hormonal modulation for body composition changes, whether alongside exercise or not, have taken a strong interest in MK-677. Other people take an interest in MK-677 for “anti-aging” effects. After all, growth hormone is often considered to be the fountain of youth,” and MK-677 will increase the natural output of growth hormone.
Let’s review a few of the most prominent effects of MK-677.
Increased Muscle Growth & Bone Density:
Muscle mass and bone density reduces with age. A significant number of older individuals experience the ill effects of osteoporosis and related complications due to decreased bone density. Simultaneously, with age, people lose skeletal muscle mass. MK-677 has shown promise in existing research to both support and increase lean muscle tissue, and improve bone density regardless of age.
MK-677 Fat Loss:
Growth hormone is a lipolytic hormone (breaks down fat), which, due to causing a simultaneous increase in IGF-1 levels, has been shown to promote fat loss and muscle development at the same time. In short, elevated growth hormone and IGF-1 levels promote a lean body composition.
MK-677 (Ibutamoren), like growth hormone, has also shown to improve sleep quality and sleep architecture (the various phases of sleep-related to brain wave patterns). Optimized sleep quality is of paramount importance to the body’s ability to be healthy, repair itself, and maintain a state of general well-being.
Improvements in Hair, Skin, and Nail Composition:
This is one of several MK-677 strengths. Increased levels of growth hormone have been shown to promote improvements in the quality and cosmetic appearance of hair, skin, and nails due to an increase in collagen synthesis.
We hope that this MK-677 Guide has provided further insight into the many unique properties of MK-677 (Ibutamoren).
Smith RG, Van der Ploeg LH, Howard AD, Feighner SD, Cheng K, Hickey GJ, Wyvratt MJ, Fisher MH, Nargund RP, Patchett AA (October 1997). “Peptidomimetic regulation of growth hormone secretion”. Endocrine Reviews. The Endocrine Society. 18 (5): 621–45. doi:10.1210/edrv.18.5.0316. PMID 9331545.http://adisinsight.springer.com/drugs/800007434
Smith RG, Thorner MO (28 January 2000). Human Growth Hormone: Research and Clinical Practice. Springer Science & Business Media. pp. 45–. ISBN 978-1-59259-015-5.
Pong SS, Chaung LY, Dean DC, Nargund RP, Patchett AA, Smith RG (January 1996). “Identification of a new G-protein-linked receptor for growth hormone secretagogues”. Molecular Endocrinology. 10 (1): 57–61. doi:10.1210/me.10.1.57. PMID 8838145.
Patchett AA, Nargund RP, Tata JR, Chen MH, Barakat KJ, Johnston DB, Cheng K, Chan WW, Butler B, Hickey G (July 1995). “Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue”. Proceedings of the National Academy of Sciences of the United States of America. 92 (15): 7001–5. doi:10.1073/pnas.92.15.7001. PMC 41459. PMID 7624358.
Holst B, Frimurer TM, Mokrosinski J, Halkjaer T, Cullberg KB, Underwood CR, Schwartz TW (January 2009). “Overlapping binding site for the endogenous agonist, small-molecule agonists, and ago-allosteric modulators on the ghrelin receptor”. Molecular Pharmacology. 75 (1): 44–59. doi:10.1124/mol.108.049189. PMID 18923064.
Cassoni P, Papotti M, Ghè C, Catapano F, Sapino A, Graziani A, Deghenghi R, Reissmann T, Ghigo E, Muccioli G (April 2001). “Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines”. The Journal of Clinical Endocrinology and Metabolism. 86 (4): 1738–45. doi:10.1210/jcem.86.4.7402. PMID 11297611.
Chapman IM, Bach MA, Van Cauter E, Farmer M, Krupa D, Taylor AM, et al. (December 1996). “Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects”. The Journal of Clinical Endocrinology and Metabolism. 81 (12): 4249–57. doi:10.1210/jcem.81.12.8954023. PMID 8954023.
Thorner MO, Chapman IM, Gaylinn BD, Pezzoli SS, Hartman ML (1997). “Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents to enhance growth hormone secretion in disease and aging”. Recent Progress in Hormone Research. 52: 215–44, discussion 244-6. PMID 9238854.
Copinschi G, Van Onderbergen A, L’Hermite-Balériaux M, Mendel CM, Caufriez A, Leproult R, Bolognese JA, De Smet M, Thorner MO, Van Cauter E (August 1996). “Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men”. The Journal of Clinical Endocrinology and Metabolism. 81 (8): 2776–82. doi:10.1210/jcem.81.8.8768828. PMID 8768828.
Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ (March 2001). “Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women”. The Journal of Clinical Endocrinology and Metabolism. 86 (3): 1116–25. doi:10.1210/jcem.86.3.7294. PMID 11238495.
Chapman IM, Pescovitz OH, Murphy G, Treep T, Cerchio KA, Krupa D, Gertz B, Polvino WJ, Skiles EH, Pezzoli SS, Thorner MO (October 1997). “Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults”. The Journal of Clinical Endocrinology and Metabolism. 82 (10): 3455–63. doi:10.1210/jc.82.10.3455. PMID 9329386.
Smith RG, Sun Y, Jiang H, Albarran-Zeckler R, Timchenko N (November 2007). “Ghrelin receptor (GHS-R1A) agonists show potential as interventive agents during aging”. Annals of the New York Academy of Sciences. 1119: 147–64. doi:10.1196/annals.1404.023. PMID 18056963.
Murphy MG, Bach MA, Plotkin D, Bolognese J, Ng J, Krupa D, Cerchio K, Gertz BJ (July 1999). “Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group”. Journal of Bone and Mineral Research. 14 (7): 1182–8. doi:10.1359/jbmr.1918.104.22.1682. PMID 10404019.